Second-line treatment and consolidation therapies in advanced ovarian cancer

Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

1996 • 1,210 citations

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

1991 • 824 citations

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

1997 • 662 citations

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1997 • 648 citations

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

1998 • 393 citations

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

1996 • 384 citations

Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer

2000 • 340 citations

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

1998 • 331 citations

Second-Line Treatment of Ovarian Cancer

2000 • 296 citations

Intraperitoneal chemotherapy: a review.

1986 • 279 citations

The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

2000 • 274 citations

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

1997 • 267 citations

Topotecan Has Substantial Antitumor Activity as First-Line Salvage Therapy in Platinum-Sensitive Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study

2000 • 200 citations

Chemotherapy of advanced ovarian cancer.

1998 • 170 citations

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.

1998 • 167 citations

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.

1994 • 167 citations

Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group

2000 • 157 citations

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.

1996 • 138 citations

Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A Randomized Trial of the Gruppo Oncologico Nord-Ovest

2000 • 137 citations

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

1996 • 135 citations

Cytoreductive Surgery in Ovarian Carcinoma Patients with a Documented Previously Complete Surgical Response

1995 • 131 citations

Docetaxel for Patients With Paclitaxel-Resistant Müllerian Carcinoma

2000 • 128 citations

Complete Salvage Surgical Cytoreduction Improves Further Survival of Patients with Late Recurrent Ovarian Cancer

2000 • 120 citations

Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer

1999 • 110 citations

Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy

1999 • 104 citations

Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer

2000 • 84 citations

A Phase II Trial of Intraperitoneal Cisplatin and Etoposide as Consolidation Therapy in Patients with Stage II–IV Epithelial Ovarian Cancer Following Negative Surgical Assessment

1998 • 82 citations

Intraperitoneal chemotherapy

1999 • 56 citations

Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer

1992 • 54 citations

Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look

1990 • 52 citations

The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

2000 • 45 citations

Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

1998 • 43 citations

A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West midlands ovarian cancer group trial II

1990 • 42 citations

Gemcitabine Salvage Chemotherapy for Patients With Gynecologic Malignancies of the Ovary, Fallopian Tube, and Peritoneum

1999 • 38 citations

A Phase I Study of a Daily ×3 Schedule of Intravenous Vinorelbine for Refractory Epithelial Ovarian Cancer

1998 • 37 citations

Gemcitabine in cisplatin-resistant ovarian cancer.

1996 • 36 citations

Up date in the management of advanced ovarian carcinoma

1999 • 35 citations

Weekly paclitaxel in the management of ovarian cancer.

2000 • 35 citations

Intraperitoneal Carboplatin with or without Interferon-α in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients

1997 • 34 citations

Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer

1994 • 31 citations

High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.

1995 • 24 citations

Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after. Second-look laparotomy

1989 • 23 citations

Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary

1992 • 23 citations

Multimodal Treatment of Ovarian Cancer

1989 • 22 citations

A novel human gene, encoding a potential membrane protein conserved from yeast to man, is strongly expressed in testis and cancer cell lines

1999 • 17 citations

32P Following Negative Second-Look Laparotomy for Epithelial Ovarian Cancer

1993 • 11 citations

A Phase I-II Trial of High-dose Ifosfamide in Patients with Ovarian Cancer Refractory or Resistant to Platinum and/or Paclitaxel-containing Chemotherapy

1999 • 11 citations

Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy--experience in an Asian population.

1998 • 7 citations

Deleted Work

1955 • 0 citations